CARLSBAD, Calif., June 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® (nusinersen) in infants and toddlers living with spinal muscular atrophy (SMA). Interim results from the RESPOND study showed improved motor function in most participants treated with SPINRAZA following treatment with Zolgensma® (onasemnogene abeparvovec). The data were presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA.
Read more at prnewswire.comNew data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.